Cabozantinib in Advanced Neuroendocrine Tumors. Reply.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Surgical management of small intestinal neuroendocrine tumours.The British journal of surgery · 2026
   Article
2. Contemporary Short-Term Outcomes of Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases.Annals of surgical oncology · 2025
   Article
3. Current Clinical Trial Landscape of Gastroenteropancreatic Neuroendocrine Tumors: A New Era of Landmark Trials.Journal of clinical medicine · 2025
   Review
4. Molecular reprogramming in thymic neuroendocrine tumors: a narrative review.Mediastinum (Hong Kong, China) · 2025
   Review

Corrections and comments

• Comment on
  Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.2025

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.